RxDoctor Payments DataLook up a doctor →

Sean Milligan, MD

Neurology · Amarillo, TXNPI 1861438061

Payments from drug & device makers

$579,662in general payments, 2019–2025

Across 1,613 payments — averaging $359.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$312K
  • AstraZeneca$170K
  • AbbVie$38K
  • Amgen$21K
  • Bristol Myers Squibb$15K
  • E.r. Squibb & Sons, L.L.C.$9K
  • plus $15K from 50 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen415$311,613
AstraZeneca299$169,864
AbbVie(2 entities)192$38,498
Amgen(2 entities)50$20,735
Bristol Myers Squibb59$15,189
E.r. Squibb & Sons, L.L.C.9$8,909
Kyowa Kirin, Inc.20$5,229
Medtronic(2 entities)16$1,205
Novartis58$877
Boston Scientific3$755
EMD Serono, Inc.40$627
Pfizer48$600
Neurocrine Biosciences, Inc.61$474
Teva Pharmaceuticals USA, Inc.49$473
Supernus Pharmaceuticals, Inc.30$433
UCB, Inc.25$415
Abbott9$365
Genentech USA, Inc.24$351
Sanofi14$261
Jazz Pharmaceuticals Inc.11$247
Revance Therapeutics, Inc.3$207
Biohaven Pharmaceutical Holding Company Ltd.34$196
Eisai Inc.8$182
SK Life Science, Inc.7$169
Axsome Therapeutics, Inc.24$168
MDD US Operations, LLC11$145
Biohaven Pharmaceuticals, Inc.23$125
Amneal Pharmaceuticals LLC9$123
ANI Pharmaceuticals, Inc.7$121
Argenx US, Inc.4$114
Akcea Therapeutics, Inc.1$99
Takeda Pharmaceuticals U.S.A., Inc.6$91
Harmony Biosciences LLC3$86
Lilly USA, LLC3$84
Lundbeck LLC3$76
Merz Pharmaceuticals, LLC3$62
Acadia Pharmaceuticals Inc4$55
Greenwich Biosciences, Inc.3$39
TG Therapeutics, Inc.2$38
Acorda Therapeutics, Inc2$36
CSL Behring2$34
Otsuka America Pharmaceutical, Inc.2$31
Ipsen Biopharmaceuticals, Inc2$31
Vanda Pharmaceuticals Inc.1$30
Bayer2$28
Mylan Institutional Inc.1$20
GE HealthCare1$19
Cycle Pharmaceuticals Inc1$18
Johnson & Johnson1$18
Promius Pharma LLC1$17
Regeneron Healthcare Solutions, Inc.1$17
Tersera Therapeutics LLC1$15
Nestle Healthcare Nutrition Inc.1$13
Phathom Pharmaceuticals, Inc.2$13
Avanir Pharmaceuticals, Inc.1$12
Impel Pharmaceuticals Inc.1$12

How this compares

$579,662 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$2,793,438
Medicare patients
1,118
Services billed
107,312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →